NEW YORK (GenomeWeb) – Consumer genomics firm Helix has forged partnerships with National Geographic, the Icahn School of Medicine at Mount Sinai, and ExploraGen, which will develop products for Helix's DNA sequencing platform, the company said today.

In addition, Helix has secured an investment of an undisclosed amount from Kleiner Perkins Caufield & Byers.

"Consumer genomics is an industry that's poised to take off as DNA data becomes more accessible," Noah Knauf, general partner at Kleiner Perkins Caufield & Byers, said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.

Oct
24
Sponsored by
OmniSeq

This webinar will discuss the advantages of a multiple-biomarker-based approach for immune profiling that provides clinicians with a rational means to consider approved immunotherapies or assign patients to immunotherapy clinical trials.

Nov
02
Sponsored by
Qiagen

This webinar will discuss the benefits of using unique molecular indices to overcome some challenges associated with next-generation sequencing panels.

Nov
09
Sponsored by
NuGEN

This webinar will discuss the role of a newly discovered, brain-enriched form of non-CpG DNA methylation in neural development and disease.

Dec
05
Sponsored by
Agilent Technologies

This webinar will discuss a molecular barcode-based error correction method that enables combined mutation detection and DNA copy number profiling through circulating tumor DNA sequencing.